PGEN (Precigen, Inc.) Stock Market Reviews

crown

search

Read and share opinions on PGEN (Precigen, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

PGEN

Precigen, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ...
Nov 14, 2025
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Nov 13, 2025
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Nov 6, 2025
Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS
Oct 26, 2025
A Look at Precigen (PGEN) Valuation Following FDA Approval of PAPZIMEOS for Recurrent Respiratory Papillomatosis
Oct 17, 2025
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Oct 13, 2025
Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization
Sep 23, 2025
Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization
Sep 20, 2025
Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS
Sep 15, 2025
Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism
Sep 11, 2025
Precigen Announces Up to $125 Million Non-Dilutive Financing
Sep 3, 2025
Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)
Sep 2, 2025

Reviews